MA44545B2 - Procédé de production d'un dérivé de diphénylméthane - Google Patents

Procédé de production d'un dérivé de diphénylméthane

Info

Publication number
MA44545B2
MA44545B2 MA44545A MA44545A MA44545B2 MA 44545 B2 MA44545 B2 MA 44545B2 MA 44545 A MA44545 A MA 44545A MA 44545 A MA44545 A MA 44545A MA 44545 B2 MA44545 B2 MA 44545B2
Authority
MA
Morocco
Prior art keywords
production
diphenylmethane derivative
synthesis
diphenylmethane
derivative
Prior art date
Application number
MA44545A
Other languages
English (en)
Other versions
MA44545B1 (fr
MA44545A1 (fr
Inventor
Hee-Kyoon Yoon
Se-Hwan Park
Ji-Sung Yoon
Soongyu Choi
Hee Jeong Seo
Eun-Jung Park
Younggyu Kong
Kwang-Seop Song
Min Ju Kim
So Ok Park
Original Assignee
Dae Woong Pharma
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA44545(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma, Green Cross Corp filed Critical Dae Woong Pharma
Publication of MA44545A1 publication Critical patent/MA44545A1/fr
Publication of MA44545B1 publication Critical patent/MA44545B1/fr
Publication of MA44545B2 publication Critical patent/MA44545B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00—Introduction of protecting groups or activating groups, not provided for in the preceding groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un procédé amélioré de production d'un dérivé de diphénylméthane qui est efficace comme inhibiteur du cotransporteur du glucose dépendant du sodium (sglt), le procédé étant exécuté à l'aide d'un procédé de synthèse convergent dans lequel chaque groupe majeur est séparément synthétisé et ensuite couplé. Ainsi, comparativement à un procédé de synthèse linéaire présenté dans les documents existants, la voie de synthèse est compacte et le rendement peut être accru, et les facteu
MA44545A 2016-06-17 2017-06-15 Procédé de production d'un dérivé de diphénylméthane MA44545B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160075910 2016-06-17
PCT/KR2017/006271 WO2017217792A1 (fr) 2016-06-17 2017-06-15 Procédé de production d'un dérivé de diphénylméthane

Publications (3)

Publication Number Publication Date
MA44545A1 MA44545A1 (fr) 2019-10-31
MA44545B1 MA44545B1 (fr) 2020-05-29
MA44545B2 true MA44545B2 (fr) 2020-11-30

Family

ID=60664449

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44545A MA44545B2 (fr) 2016-06-17 2017-06-15 Procédé de production d'un dérivé de diphénylméthane
MA50774A MA50774B1 (fr) 2016-06-17 2017-06-15 Procédé de production d'un dérivé de diphénylméthane

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA50774A MA50774B1 (fr) 2016-06-17 2017-06-15 Procédé de production d'un dérivé de diphénylméthane

Country Status (29)

Country Link
US (2) US10640496B2 (fr)
EP (2) EP3663292B1 (fr)
JP (4) JP6763978B2 (fr)
KR (2) KR102233229B1 (fr)
CN (2) CN109311861B (fr)
AU (1) AU2017285813B2 (fr)
CA (2) CA3026756C (fr)
CL (1) CL2018003645A1 (fr)
CO (1) CO2018014018A2 (fr)
DK (2) DK3663292T3 (fr)
DO (1) DOP2018000287A (fr)
EC (1) ECSP19000185A (fr)
ES (2) ES2898336T3 (fr)
HR (1) HRP20211670T8 (fr)
HU (1) HUE056428T2 (fr)
MA (2) MA44545B2 (fr)
MX (2) MX392177B (fr)
MY (1) MY203941A (fr)
NZ (1) NZ749398A (fr)
PE (2) PE20240590A1 (fr)
PH (1) PH12018550206A1 (fr)
PL (2) PL3663292T3 (fr)
PT (2) PT3473621T (fr)
RS (1) RS62550B1 (fr)
SA (2) SA521422474B1 (fr)
SG (2) SG11201811154QA (fr)
SI (1) SI3663292T1 (fr)
TN (1) TN2018000437A1 (fr)
WO (1) WO2017217792A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011054773A1 (de) 2011-10-25 2013-04-25 Vb Autobatterie Gmbh & Co. Kgaa Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols
BR112021002523A2 (pt) 2018-08-13 2021-05-04 Daewoong Pharmaceutical Co., Ltd. método para preparar um composto
CN112341416A (zh) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 一种制备苯并含氧脂杂环衍生物的方法
AU2021225706B2 (en) 2020-02-27 2024-06-13 Daewoong Pharmaceutical Co., Ltd. Intermediate useful for synthesis of SGLT inhibitor and method for preparing SGLT inhibitor using same
US12448360B2 (en) * 2020-09-10 2025-10-21 Daewoong Pharmaceutical Co., Ltd. Synthesis method for preparing SGLT inhibitor intermediate
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
CN113200860B (zh) * 2021-04-29 2024-07-30 爱斯特（成都）生物制药股份有限公司 一种sglt2抑制剂中间体的制备方法
KR20230046784A (ko) * 2021-09-30 2023-04-06 주식회사 대웅제약 이나보글리플로진을 포함하는 약학 조성물
CN113801010A (zh) * 2021-11-18 2021-12-17 山东诚创蓝海医药科技有限公司 一种5-溴-2-氯苯甲酸的制备方法
CN113912487B (zh) * 2021-11-23 2024-05-28 山东研峰新材料科技有限公司 一种2,5-双卤代苯甲酸的合成方法
KR20230110001A (ko) 2022-01-14 2023-07-21 주식회사 대웅제약 Ssglt 저해제의 합성에 유용한 중간체의 제조 방법
KR20240044190A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법
KR20240044194A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정
KR20240045138A (ko) 2022-09-29 2024-04-05 주식회사 대웅제약 이나보글리플로진을 포함하는 심혈관 노화 질환 예방 또는 치료용 약학 조성물
KR20240047952A (ko) 2022-10-05 2024-04-12 주식회사 대웅제약 이나보글리플로진을 포함하는 신장애 및/또는 당뇨병 예방 또는 치료용 약학 조성물
AU2023412900A1 (en) 2022-12-21 2025-06-12 Daewoong Therapeutics Inc. Eye drop-type pharmaceutical composition containing envogliflozin
KR20240107660A (ko) 2022-12-30 2024-07-09 주식회사 대웅제약 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물
KR102853437B1 (ko) * 2024-11-13 2025-09-04 대웅바이오(주) 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837941B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) Inline quenching 공정을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837948B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) 분배 투입법을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
RS53365B (sr) * 2003-08-01 2014-10-31 Mitsubishi Tanabe Pharma Corporation Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavisan od natrijuma
UA107175C2 (uk) 2007-07-26 2014-12-10 Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
EP2350088A1 (fr) 2008-07-30 2011-08-03 Ferrer Internacional, S.A. Composés de la 1,6-dihydro-2h-3-oxa-6-aza-as-indacene
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012041898A1 (fr) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète
CN103596564B (zh) * 2011-06-01 2016-05-04 株式会社绿十字 作为sglt2抑制剂的二苯基甲烷衍生物
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
BR112018076243A2 (pt) 2019-03-26
JP7352509B2 (ja) 2023-09-28
PE20190467A1 (es) 2019-04-04
CA3026756A1 (fr) 2017-12-21
MA44545B1 (fr) 2020-05-29
AU2017285813A1 (en) 2019-01-17
HRP20211670T1 (hr) 2022-02-18
CN113651803A (zh) 2021-11-16
KR102379584B1 (ko) 2022-03-29
CN109311861B (zh) 2021-08-24
SG10201911782RA (en) 2020-02-27
TN2018000437A1 (en) 2020-06-15
PT3473621T (pt) 2021-10-04
JP6763978B2 (ja) 2020-09-30
EP3663292B1 (fr) 2021-09-01
CA3026756C (fr) 2021-03-02
MX392177B (es) 2025-03-19
DOP2018000287A (es) 2019-03-31
RS62550B1 (sr) 2021-12-31
HRP20211670T8 (hr) 2022-03-18
DK3663292T3 (da) 2021-10-25
MA44545A1 (fr) 2019-10-31
PH12018550206A1 (en) 2019-09-30
WO2017217792A1 (fr) 2017-12-21
CA3081033A1 (fr) 2017-12-21
RU2019101056A3 (fr) 2020-07-17
MA50774B1 (fr) 2022-02-28
RU2021129636A (ru) 2021-11-22
JP2023145481A (ja) 2023-10-11
PL3663292T3 (pl) 2022-01-17
SG11201811154QA (en) 2019-01-30
MX2018015647A (es) 2019-04-11
CA3081033C (fr) 2022-04-12
NZ749398A (en) 2020-01-31
JP2019521985A (ja) 2019-08-08
US20190382390A1 (en) 2019-12-19
KR102233229B1 (ko) 2021-03-29
SI3663292T1 (sl) 2022-01-31
RU2019101056A (ru) 2020-07-17
HUE056428T2 (hu) 2022-02-28
US20190169174A1 (en) 2019-06-06
SA518400666B1 (ar) 2021-11-30
PE20240590A1 (es) 2024-03-21
PT3663292T (pt) 2021-11-08
AU2017285813B2 (en) 2020-02-06
CO2018014018A2 (es) 2019-03-08
MX385640B (es) 2025-03-18
SA521422474B1 (ar) 2023-11-02
US10889574B2 (en) 2021-01-12
JP7773506B2 (ja) 2025-11-19
US10640496B2 (en) 2020-05-05
ECSP19000185A (es) 2019-01-31
CL2018003645A1 (es) 2019-03-22
JP2020117528A (ja) 2020-08-06
EP3473621A1 (fr) 2019-04-24
ES2891825T3 (es) 2022-01-31
ES2898336T3 (es) 2022-03-07
PL3473621T3 (pl) 2022-01-10
EP3663292A1 (fr) 2020-06-10
MX2021008988A (es) 2022-05-05
JP2021152054A (ja) 2021-09-30
JP7669206B2 (ja) 2025-04-28
KR20210036892A (ko) 2021-04-05
EP3473621B1 (fr) 2021-08-04
MY203941A (en) 2024-07-25
MA50774A1 (fr) 2021-03-31
DK3473621T3 (da) 2021-09-06
KR20170142904A (ko) 2017-12-28
CN109311861A (zh) 2019-02-05
CN113651803B (zh) 2022-10-28
EP3473621A4 (fr) 2020-03-11

Similar Documents

Publication Publication Date Title
MA44545B2 (fr) Procédé de production d'un dérivé de diphénylméthane
CY1111045T1 (el) Μεθοδος παραγωγης ενος παραγωγου βενζιμιδαζολιου
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
EA201070186A1 (ru) Способы и соединения, предназначенные для получения ингибиторов котранспортера натрий-глюкозы 2 типа
EA200801622A1 (ru) Способ получения легких олефинов переработкой диметилового эфира и устройство для его осуществления
MA33368B1 (fr) Préparation de chlorhydrate de nalmefene à partir de naltrexone
MA30079B1 (fr) Procede de synthese de ferri-succinylcaseine
CY1113184T1 (el) Μεθοδος για την παρασκευη θεραπευτικως πολυτιμων παραγωγων τριφαινυλβουτενιου
FR2871341B1 (fr) Procede de production de jeunes plants et/ou de micro pieds meres de plantes ornementales herbacees.
WO2018220533A3 (fr) Procédé de production d'un composé optiquement actif
MA31603B1 (fr) Nouvelle forme cristalline du 3-(difluorométhyle)-1-méthyle-n-(3',4',5'-trifluoro[1,1'-biphenyl]-2-yl)-1h-pyrazole-4-carboxamide
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
EP1506005A4 (fr) Methodes de culture in vitro de sporozoea sp. et utilisations de ce dernier
EP4079719A4 (fr) Procédé de production d'alcool de guerbet
EA201200820A1 (ru) Способ синтеза промежуточных продуктов, применимых для получения замещенных индазолов и азаиндазолов
EP1953808A4 (fr) Procede de production d' une plaquette epitaxiale et plaquette epitaxiale
EP2211625A4 (fr) Souches fongiques et procédé de production d'un insecticide par celles-ci
NI200700175A (es) Procesos para la preparación de alcoholes de aminoetoxibencilo
EP1954134A4 (fr) Procede de synthetisation de derive 2-phenyl-1h-phenantrho[9,10-d]imidazole
FR3000641B1 (fr) Nucleon pour la culture de perles et son procede de preparation
FR3016166B1 (fr) Procede de fabrication du bromo methyl cyclopropane et du bromo methyl cyclobutane
EA200702428A1 (ru) Способы получения 4-бифенилилазетидин-2-онов
EA200802065A1 (ru) Синтез замещённых флуоренов
MA38535B1 (fr) Procédé de production d'acide 5-aminolévulinique ou d'un sel de celui-ci
EA200800466A1 (ru) Способ получения эрбумина периндоприла